The government is in the process of finalizing the 2021 Basic Policy for Economic and Fiscal Management and Reform (honebuto). This year’s policy will have a higher importance than previous ones because the drastic reforms of the drug pricing system…
HOME > ORGANIZATION
ORGANIZATION
- PhRMA Posts Its Position on Japan CEA Scheme on Website
June 11, 2021
- Eisai’s Akana Re-Elected as FPMAJ’s Drug Pricing Chief
June 11, 2021
- Terumo’s Mimura Elected New Medical Devices Chief; Reimbursement Debate Ahead for SaMD
June 9, 2021
- Experts Eye Macroeconomic Indexing of Drug Costs to Keep Innovation Afloat: INES Proposal
May 31, 2021
- Ken Suzuki Returns to JPWA Reins after 2 Years
May 28, 2021
- JPMA Positive on Use of Clinical Research Data in Submissions, but Wary of Funding Database
May 26, 2021
- Ken Suzuki Likely to Come Back as JPWA Chief after 2 Years
May 25, 2021
- JPMA Will Work towards Price Maintenance for On-Patent Medicines: New President
May 24, 2021
- Eisai’s Okada Elected as JPMA Chief, Daiichi Sankyo’s Manabe to Head FPMAJ
May 21, 2021
- JPMA Has “Different View” from US Govt on COVID-19 Vaccine IP Waiver
May 10, 2021
- EFPIA Issues Proposals for Japanese CEA System, Says “Cannot Accept” Expansion without Corrective Steps
April 21, 2021
- Regulations for DX, Pre-Symptomatic Disease Up for JPMA Committee Discussion
April 20, 2021
- Asia Trade Groups Discuss Regional Differences in Nonclinical Evaluations of Human Cell Products
April 20, 2021
- JGA Bitterly Reprimands Kobayashi Kako for Application Document Fabrication
April 20, 2021
- Asian Pharma Groups Agree to Ensure Smooth Drug Reviews amid COVID-19 Crisis
April 16, 2021
- Plaintiffs of HPV Vaccine Suits Urge LDP Group to Hear Stories of Sufferers
April 16, 2021
- Scandals Making It Difficult to Recommend Generics to Members: Kyokai Kenpo Chair
April 16, 2021
- Govt Should Set API-by-API Targets for Biosimilars: Society Chief
April 15, 2021
- Hold Off on Nichi-Iko Products for Now to Remove Generic Distrust: Pharmacy Chief
April 9, 2021
- Wakayama Council Makes List of 500 Drugs Commonly Used in Region, Snubs Nichi-Iko/Kobayashi Kako Generics
April 9, 2021
ページ
Last month, when discussing how life science manufacturers should react to the evolving pricing environment in Japan, I wrote about how manufacturers should align with stakeholders in government and the medical community on fair compensation for innovative, value creating, biopharmaceutical…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…